Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART
regimen with persistent HIV-1 viral suppression could increase the slope of decay of the
HIV-1 latent reservoir.
Phase:
Phase 3
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Collaborators:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia